Abstract
Guillain-Barré Syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation and pathogenesis. Serum antibodies against various gangliosides can be found in less than half of all patients in the acute phase of GBS but the target antigens remain unknown for the remaining half. Our work describes a comprehensive screening for serum autoantibodies targeting peripheral nerve tissue, cells, and purified antigens in a prospective GBS cohort including 100 patients. Our study confirms that (1) GBS patients display a very heterogeneous repertoire of autoantibodies targeting nerve cells and structures, (2) gangliosides are the most frequent antigens in GBS patients and have prognostic value, (3) a small subset of patients display antibodies targeting the myelin sheath, and (4) further antigen-discovery experiments are needed to elucidate other potential disease-specific autoantibodies in GBS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain and FEDER under grant FIS19/01407 and INT20/00080; and by the GBS-CIDP Foundation International. LMA was supported by a personal Rio Hortega grant CM19/00042. XSC was supported by a Sara Borrell post-doctoral fellowship project CD18/00195, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, A way to make Europe/Investing in your future). RR-G, NDL, EC-V, JT-S, EG, II and LQ are members of the ERN Euro-NMD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau and the local institutional review boards of participating hospitals or universities. All patients gave written informed consent to participate in the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work is supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain and FEDER under grant FIS19/01407 and INT20/00080; and by the GBS-CIDP Foundation International. LMA was supported by a personal Rio Hortega grant CM19/00042. XSC was supported by a “Sara Borrell” post-doctoral fellowship project “CD18/00195”, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”). RR-G, NDL, EC-V, JT-S, EG, II and LQ are members of the ERN Euro-NMD.
Data Availability
Unpublished data will be shared in an anonymized manner on request from any qualified investigator for purposes of replicating procedures and results.
